HB 391: Medical cannabis program; product labels, delivery.

Official summary

Abstract published by the legislature (via Open States). Text as published by the legislature; reproduced verbatim.

Medical cannabis program; product labels; delivery. Changes the requirements for what is included on medical cannabis product labels affixed by pharmaceutical processors to include (i) the total milligrams of tetrahydrocannabinol (THC) and cannabidiol (CBD) included in the edible cannabis product or topical cannabis product, both defined in the bill; (ii) the number of milligrams of THC and CBD in each serving of the edible cannabis product or topical cannabis product; and (iii) the total percentage of THC and CBD included in the inhalable cannabis product, defined in the bill. Under current law, the product label of any medical cannabis product is required to include the total percentage and milligrams of THC and CBD included in the product and the number of milligrams of THC and CBD in each serving.The bill also allows a pharmaceutical processor or cannabis dispensing facility to dispense or deliver cannabis products in person to a patient or such patient's registered agent, parent, or legal guardian at any residence, including a temporary residence or business. However, the bill prohibits dispensing or delivering cannabis products to (a) any military base, child day center, school, or correctional facility; (b) the State Capitol; or (c) any public gathering places, including sporting events, festivals, fairs, races, concerts, and terminals of public transportation companies. The bill also specifies that all transportation or delivery of usable cannabis, botanical cannabis, cannabis oil, or cannabis products, whether by an employee or delivery agent, shall comply with all relevant laws and regulations and provides that the Board of Directors of the Virginia Cannabis Control Authority may suspend or revoke the privileges of any employee or delivery agent to transport or deliver such products for failure to comply. The bill also provides that the 12-month stability testing period for medical cannabis products begins on the date the cannabis product is tested, rather than the date of product registration approval and that any medical cannabis product with an expiration date exceeding 12 months shall be supported by stability testing measured from the testing date, rather than the date of product registration approval. The bill contains technical amendments.

Sponsors

Sponsors by party (alphabetical): Democratic 1

“Support” is shown only as formal sponsorship recorded by the legislature. Roll-call votes are available on the official bill page.

Recent official actions

1. April 13, 2026Governor's recommendation received by House
2. March 14, 2026Governor's Action Deadline 11:59 p.m., April 13, 2026
3. March 14, 2026Enrolled Bill communicated to Governor on March 14, 2026
4. March 12, 2026Fiscal Impact Statement from Department of Planning and Budget (HB391)
5. March 10, 2026Enrolled
6. March 10, 2026Enrolled
7. March 10, 2026Signed by President
8. March 10, 2026Signed by Speaker
9. March 10, 2026Bill text as passed House and Senate (HB391ER)
10. March 10, 2026Enrolled
11. March 3, 2026Passed Senate (40-Y 0-N 0-A)
12. March 3, 2026Read third time

Showing 12 most recent of 31 actions. Full history